B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression.
Molecular biomedicine
Zhang Z, Yang N, Zeng H, Chen Y, Lu H, Xu L, Wang Z, Wang G, Zhou L, Tong A.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2026
Cancer Research
Immunology
No items found.
Key Finding
Although all three antigens were highly expressed, sustained exposure to B7-H3 CAR-T cells led to significant B7-H3 downregulation but concurrent EGFR upregulation, revealing a potential immune escape mechanism. The findings suggest that arming B7-H3 CAR-T cells with EGFR-targeting bispecific engagers represents a promising strategy to overcome antigen heterogeneity and improve therapeutic outcomes for GBM patients.
Countstar Connection
The study used Countstar (model not specified) for cell-count assessment in the study's cell samples during quality assessment in the 2026 Molecular biomedicine study.
